Products

SanBio has an expanding portfolio of products. SanBio has used its proprietary technology to develop three products, SB623 for the treatment of stroke, spinal cord injury, and Parkinson’s disease, SB618 for the treatment of multiple sclerosis and spinal cord injury, and SB308 for the treatment of muscular dystrophy and trauma.

SanBio is also exploring the opportunity to deploy its technology to produce other types of cells to address unmet medical needs. The Company believes its technology can be used to treat any degenerative disease in which the recovery of functioning cells or tissues could provide long term benefit.

SB623 (Stroke, Parkinson’s, Spinal Cord Injury)

When injected into neural tissue, SB623 and reverses neural damage. Since SB623 cells are allogeneic, a single donor’s cells can be used to treat thousands of patients.

SB618 (Multiple Sclerosis, Spinal Cord Injury)

SanBio is developing SB618 for the treatment of conditions that affect the myelin sheath of neurons such as multiple sclerosis and spinal cord injury.

CNS Drug Screening System

SanBio’s CNS Drug Screening System enables the screening of drug candidates for CNS regeneration such as stem cell differentiation and proliferation.